The first locally developed novel broad-spectrum medicine for the treatment of fungal skin diseases was created in Kazakhstan. The active substance used in the drug is roseofungin, a broad-spectrum antifungal natural antibiotic developed by the scientists at the Institute of Microbiology and Virology of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan.
Roseofungin-AS, a medicinal product for the treatment of skin fungal infections, was registered in Kazakhstan in 2017 and included in the State Register of Medicines of the Republic of Kazakhstan by the order of the Kazakh Ministry of Health.
The drug is based on antibiotic produced by a strain of microorganism isolated from the soils of Kazakhstan. This is a new natural polyene compound. The researchers found that roseofungin is active against 39 types of pathogenic fungi, including the most dangerous pathogens of superficial and deep mycoses. Further in-depth studies revealed that, along with antifungal activity, it exerts a pronounced antiviral effect and can block the reproduction of many flu viruses, paramyxoviruses, vaccinia virus, and the Rous sarcoma virus.
An industrial unit with the production line for manufacturing Roseofungin-AS ointment was established at the Institute of Microbiology and Virology. The unit is manufacturing the industrial batches of the medicine. Its current production capacity is 10-15 thousand tubes a month, and the output is expected to increase the next year.